Skip to main content
. 2021 Sep 30;12:741796. doi: 10.3389/fimmu.2021.741796

Table 1.

Descriptive analysis of the 57 families studied at the Department of Women’s and Children’s Health of the University Hospital of Padova (Italy).

Overall Children/older siblings Parents
Non-COVID-19 COVID-19 p-value § Non-COVID-19 COVID-19 p-value § Non-COVID-19 COVID-19 p-value §
(n = 54) (n = 152) (n = 30) (n = 70) (n = 24) (n = 82)
Female n (%) 23 (42.6%) 78 (51.3%) 0.27 12 (40%) 33 (47.1%) 0.51 11 (45.8%) 45 (54.9%) 0.44
Age Median (IQR) 15.6 (4.5–41.6) 28.6 (8.2–42.1) 0.33 5.4 (3.2–8.8) 8 (4.3–12.6) 0.21 42.1 (38.7–45.3) 41.7 (33.5–46.5) 0.13
Age classes n (%)
<6 years 15 (27.8%) 27 (17.8%) 0.24 15 (50%) 27 (38.6%) 0.52
6≤ age <15 12 (22.2%) 32 (21.1%) 12 (40%) 32 (45.7%)
≥15 years 27 (50%) 93 (61.2%) 3 (10%) 11 (15.7%) 24 (100%) 82 (100%)
WHO classification* n (%)
Asymptomatic 25 (16.5%) 16 (22.9%) 10 (12.2%)
Mild 119 (78.3%) 53 (75.7%) 65 (79.3%)
Moderate 6 (4%) 1 (1.4%) 5 (6.1%)
Severe 1 (0.7%) 0 (0%) 1 (1.2%)
Critical 1 (0.7%) 0 (0%) 1 (1.2%)
Pediatric comorbidities n (%)
No 27 (90%) 54 (77.1%) 0.13
Yes** 3 (10%) 16 (22.9%)

§Student’s t-test, χ2 test, Fisher exact test where appropriate.

*WHO, World Health Organization.

**The following co-morbidities were found among 16 COVID-19 positive children: premature birth (n = 1), asthma (n = 5), allergy (n = 1), congenital heart disease (n = 1), rheumatic disease (n = 1), chronic neuropathy (n = 1), immune deficiency (n = 2), cleft lip and palate (n = 1), and kidney/ureteral disease (n = 1).